- Home
- PTMN vs GNLX Comparison
PTMN vs GNLX Comparison
Compare PTMN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTMN
- GNLX
- Stock Information
- Founded
- PTMN 2006
- GNLX 2001
- Country
- PTMN United States
- GNLX United States
- Employees
- PTMN N/A
- GNLX N/A
- Industry
- PTMN Finance: Consumer Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- PTMN Finance
- GNLX Health Care
- Exchange
- PTMN Nasdaq
- GNLX Nasdaq
- Market Cap
- PTMN 113.0M
- GNLX 94.0M
- IPO Year
- PTMN N/A
- GNLX 2023
- Fundamental
- Price
- PTMN $11.77
- GNLX $2.71
- Analyst Decision
- PTMN Hold
- GNLX Strong Buy
- Analyst Count
- PTMN 1
- GNLX 4
- Target Price
- PTMN $14.00
- GNLX $17.75
- AVG Volume (30 Days)
- PTMN 47.8K
- GNLX 144.5K
- Earning Date
- PTMN 05-08-2025
- GNLX 05-06-2025
- Dividend Yield
- PTMN 20.38%
- GNLX N/A
- EPS Growth
- PTMN N/A
- GNLX N/A
- EPS
- PTMN N/A
- GNLX N/A
- Revenue
- PTMN $58,024,000.00
- GNLX N/A
- Revenue This Year
- PTMN N/A
- GNLX N/A
- Revenue Next Year
- PTMN $12.20
- GNLX N/A
- P/E Ratio
- PTMN N/A
- GNLX N/A
- Revenue Growth
- PTMN N/A
- GNLX N/A
- 52 Week Low
- PTMN $11.54
- GNLX $1.60
- 52 Week High
- PTMN $19.95
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- PTMN 39.22
- GNLX 54.37
- Support Level
- PTMN $11.54
- GNLX $2.38
- Resistance Level
- PTMN $12.84
- GNLX $2.60
- Average True Range (ATR)
- PTMN 0.25
- GNLX 0.19
- MACD
- PTMN -0.00
- GNLX 0.03
- Stochastic Oscillator
- PTMN 27.38
- GNLX 78.76
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.